Despite achieving similar response rates to traditional chemotherapy, patients with FLT3-mutated AML have a higher likelihood of relapse than patients with WT-FLT3 AML, even after undergoing allogeneic hematopoietic stem cell transplantation (HSCT) [49]. Here, FLT3 is linked to acute myeloid leukemia.